United-Guardian, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; filed May 8, 2012. The company develops, manufactures, and markets personal care, pharmaceutical, medical, and specialty industrial products. Its LUBRAJEL line is a key personal care product line.
Financial performance
- Net sales: $3.889 million, up 6.8% from $3.642 million in Q1 2011.
- Income from operations: $1.746 million, up 5.2%. Gross margin was approximately 60.4%, versus 59.9%; operating margin was approximately 44.9%, versus 45.6%.
- Net income: $1.229 million, up 5.4%; diluted and basic EPS were $0.27, versus $0.25. Net margin was approximately 31.6%, versus 32.0%.
- Cash flow: Operating cash flow was $2.054 million, versus $1.423 million. Investing activities used $1.563 million, mainly for marketable-security purchases; capital expenditures were $66,870. Cash increased $491,214 to $1.582 million.
- Liquidity: Working capital was $14.219 million, up from $12.895 million at year-end 2011. The current ratio was 11.0, compared with 13.0. Cash and marketable securities totaled $12.466 million.
- Debt and equity: No borrowings are reported on the presented balance sheet. Total liabilities were $1.521 million and stockholders’ equity was $15.405 million at March 31, 2012.
- Other metrics: Effective tax rate was approximately 33% in both periods. Research and development expense was $146,342, versus $127,271. No dividends were paid during either first quarter.
Material changes and management commentary
- Pharmaceutical gross sales rose 138.9%, primarily because RENACIDIN had normal production and availability in Q1 2012; its sole supplier had temporarily curtailed production in late 2010 through early 2011 for regulatory issues unrelated to the product.
- Personal care gross sales increased 5.0%, including a 6.8% increase in sales to the largest marketing partner. Medical product sales declined 26.9%, which management attributed primarily to order timing; industrial and miscellaneous product sales declined 25.1%.
- Cost of sales fell to 39.6% of sales from 40.1%, reflecting lower payroll, utility, and insurance costs. Operating expenses increased 15.7%, mainly from advertising, payroll-related costs, and real estate taxes.
- Management said working capital should be sufficient for operating needs for at least 12 months and does not expect significant capital expenditures for the remainder of 2012. It expects to use cash for dividends, marketable-security purchases, and other opportunities; no specific dividend amount or earnings guidance was provided.
- Marketable securities were $10.884 million, all available-for-sale and measured using Level 1 quoted prices. Q1 included $6,489 of realized investment losses and $62,184 of after-tax other comprehensive income from unrealized gains.
Risks, contingencies, and controls
- Risks cited include product-development and market-acceptance uncertainty, product quality or composition changes, competition, intellectual property, economic and industry conditions, interest rates, regulatory changes, and securities-market conditions.
- Approximately half of products are sold to end users outside the United States. ASI is the largest marketing partner; RENACIDIN depends on a sole supplier.
- Receivables averaged 37 days outstanding, versus 35 days a year earlier; management cited slower payment by a few customers.
- The company reported no off-balance-sheet arrangements and no legal proceedings. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the RENACIDIN supply arrangement remains reliable and whether pharmaceutical sales growth is sustainable after comparison with the prior-year production disruption.
- Whether sales to the largest marketing partner, overseas customers, and key product categories remain stable, particularly given the medical-product decline.
- Whether slower collections, the increase in income taxes payable, and changes in accrued expenses affect future operating cash flow.
- The composition, maturity profile, and market-value sensitivity of the company’s substantial marketable-securities portfolio.
- Future dividend decisions and whether management’s stated liquidity and capital-expenditure expectations change.